Hologic accelerates restructuring following Gen-Probe takeover

Hologic has announced that it will be accelerating a series of previously-announced corporate restructuring measures thanks to the better-than-expected progress it has achieved in its takeover and integration of Gen-Probe.

The company is successfully incorporating the business – which was acquired in August 2012 – into its diagnostics segment and is on track to realise more than $40 million (25.18 million pounds) in cost synergies by the end of the first year.

This process is proceeding ahead of schedule, leading Hologic to announce that Carl Hull – formerly the chief executive officer of Gen-Probe – will be retiring from his role as senior vice-president and general manager of diagnostics earlier than planned.

Rohan Hastie, the former vice-president and general manager of Hologic's women's health division, will take over this role, while Eric Tardif has been named senior vice-president of corporate strategy.

Rob Cascella, president and chief executive officer of Hologic, said: "We are grateful for the deep bench of talent within the Hologic and legacy Gen-Probe organisations who are well positioned to successfully assume greater levels of responsibility as we continue to grow."

This comes after the firm announced the sale of its Lifecodes business to Immucor earlier this month.